Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine

Fig. 2

Organoids from primary PCa retain features of originating tumor. A Diagram displaying the mapping of tumor foci of patient derived tumors and NAT tissue for successful organoid generation. B Representative data from primary PCa PDOs demonstrating retention of the PCa specific genetic alterations such as TMPRSS-Erg fusion. The upper panel demonstrates H&E and IHC staining for Erg (brown) from TMPRSS-Erg fusion co-staining with PCa specific AMACR (red). Fluorescent In Situ Hybridization (FISH) for detecting TMPRSS-Erg fusion. IHC staining could also be used to detect tumor infiltrating lymphocytes (CD8+, brown) and tumor microenviromental mapping (SMA+, red). The lower panel demonstrates IF staining of single cell derived organoids. The lower panel demonstrates representative images of PDOs derived from single cells and examined on Day 21 for differentiation into lineage specific prostatic cells. PDOs are predominantly showing luminal PSA positive cells (red) and a surrounding layer of basal cytokeratin (CK14, green) localized to periphery. Scale bars are 100 μm in H&E and IF/IHC images and 10 μm in the FISH image

Back to article page